History and impact of the mouse-adapted Ebola virus model

Ebola virus (EBOV) is a member of the filoviridae family, which are comprised of negative sense, enveloped RNA hemorrhagic fever viruses that can cause severe disease and high lethality rates. These viruses require BSL-4 containment laboratories for study. Early studies of EBOV pathogenesis relied heavily on the use of nonhuman primates, which are expensive and cumbersome to handle in large numbers. Guinea pig models were also developed, but even to this day limited reagents are available in this model. In 1998, Mike Bray and col-leagues developed a mouse-adapted EBOV (maEBOV) that caused lethality in adult immunocompetent mice. This model had significant advantages, including being inexpensive, allowing for higher animal numbers for statis-tical analysis, availability of reagents for studying pathogenesis, and availability of a vast array of genetically modified strains. The model has been used to test vaccines, therapeutic drugs, EBOV mutants, and pathogenesis, and its importance is demonstrated by the hundreds of citations referencing the original publication. This review will cover the history of the maEBOV model and its use in filovirus research.

Automated summary

Ebola virus (EBOV) belongs to the filoviridae family and can cause severe disease and high lethality rates. A mouse-adapted EBOV (maEBOV) model has been developed, which has significant advantages in terms of cost, availability of reagents, and genetically modified strains. The model has been widely used in studying vaccines, therapeutic drugs, EBOV mutants, and pathogenesis, and has received numerous citations. This review will discuss the history and use of the maEBOV model in filovirus research.